Developing drugs to reduce the effects or onset of Alzheimer’s Disease


Notice: Trying to access array offset on value of type bool in /home/onliiuxo/public_html/wp-content/themes/betheme/functions/theme-functions.php on line 1490

Notice: Trying to access array offset on value of type bool in /home/onliiuxo/public_html/wp-content/themes/betheme/functions/theme-functions.php on line 1495

Developing drugs to reduce the effects or onset of Alzheimer’s Disease


Notice: Trying to access array offset on value of type bool in /home/onliiuxo/public_html/wp-content/themes/betheme/functions/theme-functions.php on line 1490

Notice: Trying to access array offset on value of type bool in /home/onliiuxo/public_html/wp-content/themes/betheme/functions/theme-functions.php on line 1495

Assume there is a well-financed, one-year-old company in the biotech industry that is concentrating on developing chemical-based compounds that are aimed at developing drugs to reduce the effects or onset of Alzheimer’s Disease. What financial information (ratios or otherwise) would you think would be relevant or irrelevant from the viewpoint of possible investors in this company?